

AMENDMENTS

IN THE CLAIMS:

Kindly amend the claims as follows:

Please cancel claims 3, 4, and 5.

Please amend claims 1, 2, 6, 7, and 8, as shown in the attached page (page 4 of this amendment).

REMARKS

Applicants respectfully request reconsideration and reexamination of the present application in light of the amendments and the remarks below.

Claims 1, 2, and 6-10 are pending in this application. Claims 3, 4, and 5 have been cancelled. Claims 1, 2, 6, 7, and 8 have been amended. These claim amendments are made to clarify the subject matter therein. Therefore, these amendments are submitted in order to place the claims in condition for allowance, and do not disclaim any subject matter to which the Applicants are entitled.

Advisory Action

The Examiner has maintained the rejection of claims 1-10 (Paper No. 20041204). To expedite the prosecution of the pending application, the claims have been amended. Specifically, the claims 1, 2, 6, 7, and 8 have been amended to recite permethrin and imidacloprid.

It is thus submitted that the claims 1, 2, and 6-10 are allowable.

CONCLUSION


For the foregoing reasons, Applicants submit that the claims are in condition for allowance and Applicants respectfully request reexamination of the present application, reconsideration and withdrawal of the present rejections, and entry of the amendments. Should there be any further matter requiring consideration, Examiner Qazi is invited to contact the undersigned counsel.

If there are any further fees due in connection with the filing of the present reply, please charge the fees to undersigned's Deposit Account No. 13-3372. If a fee is required for an extension of time not accounted for, such an extension is requested and the fee should also be charged to undersigned's deposit account.

Respectfully submitted,

March 24, 2004

Bayer Pharmaceuticals Corporation
400 Morgan Lane
West Haven, CT 06516-4175
Telephone: (203) 812-6450
Facsimile: (203) 812-6459


Susan M. Pellegrino
Reg. No. 48,972